Selected research
Industry Research
Sexual Dysfunction Drugs Industry Research Report 2026
Market perspective
The global Sexual Dysfunction Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Sexual Dysfunction Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Sexual Dysfunction Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Sexual Dysfunction Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Sexual Dysfunction Drugs include Takeda, Teva Pharmaceutical Industries, Merck, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer, AbbVie and Vietstar Biomedical Research, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Sexual Dysfunction Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sexual Dysfunction Drugs Market by Company
Takeda
Teva Pharmaceutical Industries
Merck
Eli Lilly
Pfizer
GlaxoSmithKline
Bayer
AbbVie
Vietstar Biomedical Research
S1 Biopharma
NexMed
Leadiant Biosciences
Ivix LLX
Emotional Brain
Apricus Biosciences
Sexual Dysfunction Drugs Segment by Type
Hormonal Therapy
Transurethral Therapy
Oral Therapy
Intracavernosal Therapy
Sexual Dysfunction Drugs Segment by Application
Male
Female
Sexual Dysfunction Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sexual Dysfunction Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sexual Dysfunction Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sexual Dysfunction Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Sexual Dysfunction Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Sexual Dysfunction Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Sexual Dysfunction Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hormonal Therapy
- Transurethral Therapy
- Oral Therapy
- Intracavernosal Therapy
Applications
- Male
- Female
Companies covered
- Takeda
- Teva Pharmaceutical Industries
- Merck
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Bayer
- AbbVie
- Vietstar Biomedical Research
- S1 Biopharma
- NexMed
- Leadiant Biosciences
- Ivix LLX
- Emotional Brain
- Apricus Biosciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Sexual Dysfunction Drugs Market Size (2021-2032)
- 2.2.2 Global Sexual Dysfunction Drugs Sales (2021-2032)
- 2.2.3 Global Sexual Dysfunction Drugs Market Average Price (2021-2032)
- 2.3 Sexual Dysfunction Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Hormonal Therapy
- 2.3.3 Transurethral Therapy
- 2.3.4 Oral Therapy
- 2.3.5 Intracavernosal Therapy
- 2.4 Sexual Dysfunction Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Male
- 2.4.3 Female
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Sexual Dysfunction Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sexual Dysfunction Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Sexual Dysfunction Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Sexual Dysfunction Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Sexual Dysfunction Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sexual Dysfunction Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sexual Dysfunction Drugs, Product Type & Application
- 3.8 Global Manufacturers of Sexual Dysfunction Drugs, Established Date
- 3.9 Global Sexual Dysfunction Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Sexual Dysfunction Drugs Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Teva Pharmaceutical Industries
- 4.2.1 Teva Pharmaceutical Industries Company Information
- 4.2.2 Teva Pharmaceutical Industries Business Overview
- 4.2.3 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Pharmaceutical Industries Sexual Dysfunction Drugs Product Portfolio
- 4.2.5 Teva Pharmaceutical Industries Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Sexual Dysfunction Drugs Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Eli Lilly
- 4.4.1 Eli Lilly Company Information
- 4.4.2 Eli Lilly Business Overview
- 4.4.3 Eli Lilly Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lilly Sexual Dysfunction Drugs Product Portfolio
- 4.4.5 Eli Lilly Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Sexual Dysfunction Drugs Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 GlaxoSmithKline
- 4.6.1 GlaxoSmithKline Company Information
- 4.6.2 GlaxoSmithKline Business Overview
- 4.6.3 GlaxoSmithKline Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline Sexual Dysfunction Drugs Product Portfolio
- 4.6.5 GlaxoSmithKline Recent Developments
- 4.7 Bayer
- 4.7.1 Bayer Company Information
- 4.7.2 Bayer Business Overview
- 4.7.3 Bayer Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bayer Sexual Dysfunction Drugs Product Portfolio
- 4.7.5 Bayer Recent Developments
- 4.8 AbbVie
- 4.8.1 AbbVie Company Information
- 4.8.2 AbbVie Business Overview
- 4.8.3 AbbVie Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AbbVie Sexual Dysfunction Drugs Product Portfolio
- 4.8.5 AbbVie Recent Developments
- 4.9 Vietstar Biomedical Research
- 4.9.1 Vietstar Biomedical Research Company Information
- 4.9.2 Vietstar Biomedical Research Business Overview
- 4.9.3 Vietstar Biomedical Research Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Vietstar Biomedical Research Sexual Dysfunction Drugs Product Portfolio
- 4.9.5 Vietstar Biomedical Research Recent Developments
- 4.10 S1 Biopharma
- 4.10.1 S1 Biopharma Company Information
- 4.10.2 S1 Biopharma Business Overview
- 4.10.3 S1 Biopharma Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 S1 Biopharma Sexual Dysfunction Drugs Product Portfolio
- 4.10.5 S1 Biopharma Recent Developments
- 4.11 NexMed
- 4.11.1 NexMed Company Information
- 4.11.2 NexMed Business Overview
- 4.11.3 NexMed Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 NexMed Sexual Dysfunction Drugs Product Portfolio
- 4.11.5 NexMed Recent Developments
- 4.12 Leadiant Biosciences
- 4.12.1 Leadiant Biosciences Company Information
- 4.12.2 Leadiant Biosciences Business Overview
- 4.12.3 Leadiant Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Leadiant Biosciences Sexual Dysfunction Drugs Product Portfolio
- 4.12.5 Leadiant Biosciences Recent Developments
- 4.13 Ivix LLX
- 4.13.1 Ivix LLX Company Information
- 4.13.2 Ivix LLX Business Overview
- 4.13.3 Ivix LLX Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ivix LLX Sexual Dysfunction Drugs Product Portfolio
- 4.13.5 Ivix LLX Recent Developments
- 4.14 Emotional Brain
- 4.14.1 Emotional Brain Company Information
- 4.14.2 Emotional Brain Business Overview
- 4.14.3 Emotional Brain Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Emotional Brain Sexual Dysfunction Drugs Product Portfolio
- 4.14.5 Emotional Brain Recent Developments
- 4.15 Apricus Biosciences
- 4.15.1 Apricus Biosciences Company Information
- 4.15.2 Apricus Biosciences Business Overview
- 4.15.3 Apricus Biosciences Sexual Dysfunction Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Apricus Biosciences Sexual Dysfunction Drugs Product Portfolio
- 4.15.5 Apricus Biosciences Recent Developments
5 Global Sexual Dysfunction Drugs Market Scenario by Region
- 5.1 Global Sexual Dysfunction Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sexual Dysfunction Drugs Sales by Region: 2021-2032
- 5.2.1 Global Sexual Dysfunction Drugs Sales by Region: 2021-2026
- 5.2.2 Global Sexual Dysfunction Drugs Sales by Region: 2027-2032
- 5.3 Global Sexual Dysfunction Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Sexual Dysfunction Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Sexual Dysfunction Drugs Revenue by Region: 2027-2032
- 5.4 North America Sexual Dysfunction Drugs Market Facts & Figures by Country
- 5.4.1 North America Sexual Dysfunction Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Sexual Dysfunction Drugs Sales by Country (2021-2032)
- 5.4.3 North America Sexual Dysfunction Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Sexual Dysfunction Drugs Market Facts & Figures by Country
- 5.5.1 Europe Sexual Dysfunction Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Sexual Dysfunction Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Sexual Dysfunction Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Sexual Dysfunction Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Sexual Dysfunction Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Sexual Dysfunction Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Sexual Dysfunction Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Sexual Dysfunction Drugs Market Facts & Figures by Country
- 5.7.1 South America Sexual Dysfunction Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Sexual Dysfunction Drugs Sales by Country (2021-2032)
- 5.7.3 South America Sexual Dysfunction Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Sexual Dysfunction Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Sexual Dysfunction Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Sexual Dysfunction Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Sexual Dysfunction Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Sexual Dysfunction Drugs Sales by Type (2021-2032)
- 6.1.1 Global Sexual Dysfunction Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Sexual Dysfunction Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Sexual Dysfunction Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Sexual Dysfunction Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Sexual Dysfunction Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Sexual Dysfunction Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Sexual Dysfunction Drugs Sales by Application (2021-2032)
- 7.1.1 Global Sexual Dysfunction Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Sexual Dysfunction Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Sexual Dysfunction Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Sexual Dysfunction Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Sexual Dysfunction Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Sexual Dysfunction Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Sexual Dysfunction Drugs Value Chain Analysis
- 8.1.1 Sexual Dysfunction Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Sexual Dysfunction Drugs Production Mode & Process
- 8.2 Sexual Dysfunction Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Sexual Dysfunction Drugs Distributors
- 8.2.3 Sexual Dysfunction Drugs Customers
9 Global Sexual Dysfunction Drugs Analyzing Market Dynamics
- 9.1 Sexual Dysfunction Drugs Industry Trends
- 9.2 Sexual Dysfunction Drugs Industry Drivers
- 9.3 Sexual Dysfunction Drugs Industry Opportunities and Challenges
- 9.4 Sexual Dysfunction Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst